Trials / Recruiting
RecruitingNCT06387212
35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin
35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Skin Inflammation
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Nakhia Impex LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 35 kDa hyaluronan fragment HA35 injection | First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ). |
Timeline
- Start date
- 2024-04-15
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
- First posted
- 2024-04-26
- Last updated
- 2024-05-21
Locations
1 site across 1 country: Mongolia
Source: ClinicalTrials.gov record NCT06387212. Inclusion in this directory is not an endorsement.